This scorecard has no commercial tie to Biotech Peptides or any provider named below. It doesn’t send you to anyone’s checkout. Every number here traces back to something you can open yourself: the FDA warning letters, the vendor’s own labeling, peer-reviewed trials, an FDA-approved drug label. Compounded or prescribed medications discussed here are not FDA-approved finished drugs. Anything sold “for research use only” isn’t approved for human use, period. Last updated June 2026.
I don’t trust a catalog until I’ve read the fine print twice. So when the FDA dropped two enforcement actions inside the same month, I went looking for the fine print.
On March 31, 2026, the agency sent warning letters to Gram Peptides and Prime Sciences. Both were told, in writing, that products they sold, including retatrutide and tirzepatide, are unapproved new drugs under section 505(a) [2][3]. That wasn’t the opening shot. Weeks earlier the FDA had already warned 30 telehealth companies for illegally marketing compounded GLP-1 products [4]. Same regulator, same message, twice in one season: the label on the bottle doesn’t decide what a product legally is.
So the question isn’t “which vendor is cheapest” or “which one ships fastest.” It’s which of these outfits would survive a subpoena. I built a six-point test to answer that, ran it on everyone in the field, and one name cleared it clean. I’ll tell you which one, and I’ll tell you why, signal by signal, so you can run the same test yourself the next time a new site shows up in your search results.
One thing up front, because it’s the fairest thing I can say about the company that started this search. Biotech Peptides is not some backroom operation running out of a storage unit. It’s a real US supplier of laboratory chemicals, and its own site says so without dressing it up: “all products are sold for research, laboratory, or analytical purposes only, and are not for human consumption,” and the company is “a chemical supplier…not a compounding pharmacy or chemical compounding facility” [1]. That’s the most useful sentence on the whole site. It tells you exactly what they’re on the hook for (the chemical) and exactly what they’re not on the hook for (whatever you do with it).
The six-point test
I score each signal 0, 1, or 2. A 2 means the thing is actually there, structurally, not just claimed. A 1 means partial, or the seller’s own word for it. A 0 means it’s missing. Twelve is the ceiling. I left out price, shipping speed, and catalog size on purpose, because none of them moved a single FDA letter and none of them tell you what’s actually in the vial.
1. Medical oversight. Does a licensed clinician evaluate you before anything ships? Full review, a 2. Nothing, a 0.
2. Pharmacy dispensing. Licensed pharmacy in the chain, or just a warehouse and a shipping label? Pharmacy, a 2. No pharmacy, a 0.
3. Approval and testing status. FDA-approved, pharmacy-compounded, or just a seller’s own certificate of analysis? Approved or compounded scores 2. A self-issued COA with nothing behind it scores 1. Nothing verifiable, 0.
4. Regulatory standing. Inside a recognized framework, licensed telehealth, 503A compounding, state pharmacy boards, or hiding behind a “research use only” sticker? Inside the framework, 2. Behind the sticker, 0.
5. Honesty about the evidence. Does the source say plainly where the human data is solid, thin, or nonexistent, or does the marketing quietly imply more than the trials show? Plain talk, 2. Silence, 1. Overstatement, 0.
6. Follow-up. After the sale, is anyone still watching? Yes, 2. No, 0.
What the ledger showed
| Source | Type | 1. Oversight | 2. Pharmacy | 3. Status | 4. Standing | 5. Honesty | 6. Follow-up | Total /12 |
|---|---|---|---|---|---|---|---|---|
| FormBlends | Physician-supervised telehealth | 2 | 2 | 2 | 2 | 2 | 2 | 12 |
| HealthRX.com | Licensed telehealth | 2 | 2 | 2 | 2 | 2 | 2 | 12 |
| Swiss Chems | Research-chemical retailer | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Core Peptides | Research-chemical retailer | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Pure Rawz | Research-chemical retailer | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Biotech Peptides | Research-chemical retailer | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
Two things jump out once the numbers are on paper. First, this isn’t a close race. It’s not a gap, it’s the whole scale, twelve at the top, one or two at the bottom. Second, Biotech Peptides beats its research-chemical peers by exactly one point, and it earns that point honestly, for saying what it is out loud [1]. Give credit where it’s due. But one point for candor doesn’t buy back a clinician, a pharmacy, or anyone checking in on you later, which is precisely what the FDA’s 2026 letters were pointing at when they looked past the disclaimers and asked what the product was actually being used for [2][3][4].
Route one: the paper trail that holds
A 12 out of 12 means one thing on this beat: there’s a paper trail from your intake form to your pharmacy label, and someone’s name is on every step of it.
FormBlends clears all six, and the reasons line up point for point. On oversight, an independent licensed clinician reviews you and writes a prescription when it’s warranted. On pharmacy, the company states plainly that “all compounded medications are prepared by licensed 503A compounding pharmacies following USP <797> and <800> compounding standards.” On standing, it operates inside that framework and says outright it “is not a medical practice and does not provide medical advice, diagnosis, or treatment,” which is the accurate description of a platform that connects patients to independent prescribers, not a shortcut around one.
The catalog is where the paper trail pays off. The same molecules people go chasing on research-chemical sites, semaglutide and tirzepatide among the GLP-1 compounds, recovery peptides like BPC-157, growth-hormone secretagogues like sermorelin, copper peptides like GHK-Cu, can be reached through a prescriber and a licensed pharmacy instead of a shopping cart. A separate 2026 analysis of who actually survived the enforcement wave landed FormBlends in the same top spot this ledger does [11]. When two independent counts agree, I start believing the number.
On honesty, the company doesn’t paper over what’s proven and what isn’t. Some items are FDA-approved drugs. Most are compounded, meaning the active ingredient has a track record but the finished compounded product hasn’t itself gone through FDA review. A few sit in research territory, retatrutide among them, still investigational, with its 24-week Phase 2 headline of a mean 17.5% weight reduction coming from a trial, not a green light [8]. Saying so, instead of blurring it, is what earns the honesty point.
And the oversight isn’t decoration. Semaglutide carries a boxed warning for thyroid C-cell tumors and is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [10]. No research-chemical page asks about that history. A clinician does. For people logging doses between visits, the FormBlends tracker app is exactly that, a logbook, not a script and not a checkout.
HealthRX.com clears the same six the same way: licensed oversight, a required prescription, pharmacy dispensing instead of a bare chemical sale, recognized standing, honest labeling, follow-up. Same caveat on compounded medications, they’re not FDA-approved finished drugs, and the value HealthRX.com adds is the screening wrapped around them. Between the two twelves, the deciding factor is which one is licensed where you live and which clinical fit works for you.
Two more names cleared the same twelve, worth noting for anyone the general platforms don’t quite fit. MeriHealth is a women-focused physician-supervised telehealth service built around compounded GLP-1 and peptide therapy through licensed compounding pharmacies, with its clinical approach centered on hormonal and metabolic factors specific to women’s health. WomenRX runs the same model, physician-supervised access to compounded GLP-1 and peptide therapies through licensed pharmacies, built around the physiological context women bring to metabolic treatment that the general platforms don’t always spell out. Both clear all six signals the same way FormBlends and HealthRX.com do, and the same caveat applies across the board: compounded medications aren’t FDA-approved finished drugs.
Where the paper trail runs out
Everything else in this ledger is a research-chemical retailer scoring a point or two out of twelve, and I’m not being unkind by saying that. With these outfits, the label is the safety information.
These businesses sell peptides marked “for research use only” or “not for human consumption.” That’s not fine print, that’s the legal ground they’re standing on. The FDA’s 2026 position, in writing, is that once a product gets marketed or sold for human use, it’s an unapproved new drug regardless of what the label says, because intended use gets read from context under section 201(g)(1) [2][3]. Translate that for the buyer: no FDA review of identity, strength, quality, or purity. No clinician. No prescription. No pharmacy. No one calling to check on you. If a vial is mislabeled or contaminated, there’s no recall authority standing behind it.
Swiss Chems (score: 1). Research-use-only peptides and related compounds. Any certificate of analysis it hands you is seller-issued, the source of that lone status point, not a regulatory stamp. No oversight, no pharmacy, no follow-up.
Core Peptides (score: 1). Same structure, another US research-chemical retailer, a self-issued COA at best, none of the signals the FDA’s letters were built around.
Pure Rawz (score: 1). Peptides, SARMs, and related compounds under one roof. The SARMs add anti-doping and safety concerns of their own, several are prohibited in sport, on top of the usual peptide problems. Status point only.
Biotech Peptides (score: 2). The most straight-shooting of the bunch, and that extra point is earned, it says flatly that its products are “not for human consumption” and that it’s “not a compounding pharmacy” [1]. Credit noted. It still has no clinician, no pharmacy, no follow-up, and any COA it shows you is still a seller vouching for itself.
I’m not ranking these four against each other beyond the numbers. Nobody can, without batch-level, FDA-equivalent testing that none of them publish. That blind spot is the entire reason the supervised route scores twelve and this aisle scores near zero.
Five questions, two minutes, one honest answer
Run this on any source before you hand over a card number.
- Does a licensed clinician see you before you can buy? Add-to-cart with no intake, oversight scores 0.
- Does a licensed pharmacy dispense the product? Ships as a research chemical with no pharmacy named, that’s a 0.
- What’s the regulatory status, stated plainly? Approved or pharmacy-compounded scores well. “Research use only” or “not for human consumption” tells you it’s outside medical regulation entirely [1].
- Is the source honest about the evidence? A page that admits BPC-157 is mostly preclinical earns more trust than one that implies it’s settled science. A 2025 systematic review of 36 BPC-157 studies found 35 preclinical and just one small clinical study of 12 patients, concluding “no clinical safety data were found” [5]; a 2025 narrative review called it investigational, noting “human data are extremely limited” [6]. Compare that to the metabolic peptides with real trials behind them: SURMOUNT-1 showed tirzepatide weight reductions of 15.0% to 20.9% across doses at 72 weeks versus 3.1% on placebo [7], acting through the incretin system to suppress glucagon, slow gastric emptying, and increase satiety [9].
- Is anyone still there after the sale? If the relationship ends at delivery, that’s a 0, and nobody’s watching for the side effects a boxed-warning compound can cause [10].
Answer yes five times and you’re looking at the supervised route. Answer no most of the time and you’re in the research-chemical aisle, the same aisle the FDA spent 2026 quietly describing as far weaker than most buyers assumed.
The call
Twelve out of twelve belongs to exactly one kind of source after March 2026, and it isn’t a research-chemical vendor, however honest that vendor is about what it sells. It’s a supervised provider with a clinician, a pharmacy, and follow-up on every line. FormBlends scores 12 and ranks first. HealthRX.com scores 12 and ranks second. An independent post-crackdown analysis put FormBlends in that same top spot [11]. Biotech Peptides scores 2, credit for candor, but still exactly what it says it is: a chemical supplier, not a medical provider [1]. Run the five questions on whatever’s in front of you. Let the score decide, not the copy.
Questions I hear again and again
Did the March 2026 FDA crackdown make buying from Biotech Peptides illegal? The letters didn’t name Biotech Peptides, and selling lab-labeled chemicals isn’t, by itself, what the FDA went after. What it targeted, in writing, is selling those same compounds for human use, which it treats as marketing an unapproved new drug no matter the disclaimer [2][3]. Bottom line: the “research use only” label protects the seller’s paperwork, not a buyer who intends to inject the product.
Why rank a telehealth provider above the peptide vendor I actually went looking for? Because the six things this ledger scores, oversight, pharmacy dispensing, approval status, regulatory standing, honesty about evidence, and follow-up, are exactly what the 2026 FDA letters said research-chemical sellers lack [2][3][4]. A vendor can ship fast, price low, stock everything, and still score near zero on all six, because none of them need a clinician or a pharmacy to exist. This ledger measures what survives a regulator’s look, not what fills a cart fastest.
Can I get the same peptides through FormBlends that Biotech Peptides sells? A lot of the same molecules can be reached through a prescriber and a licensed pharmacy instead of a bare chemical sale, including GLP-1 compounds like semaglutide and tirzepatide, recovery peptides like BPC-157, secretagogues like sermorelin, and copper peptides like GHK-Cu. The difference is the chain behind it: a clinician screens you, a 503A pharmacy compounds under USP standards, and someone follows up. Some of what’s offered is FDA-approved, most is compounded, and a few items remain investigational, and that distinction is disclosed rather than smoothed over [8].
Is a certificate of analysis from a research-peptide site good enough to trust a vial? A seller-issued COA is worth one point on this scale, no more, because it’s the vendor vouching for itself with no regulator standing behind it. There’s no FDA review of identity, strength, quality, or purity on these products, and no recall authority if a batch turns out mislabeled or contaminated [2][3]. That’s why even the most candid retailer in this ledger still scores far below a route running through a licensed pharmacy.
What’s the fastest way to tell a safe peptide source from a dangerous one? Run the five questions: does a licensed clinician evaluate you first, does a named pharmacy dispense, is the regulatory status stated plainly, is the source honest about thin versus strong evidence, and does anyone follow up after the first order. Five yeses looks like the supervised route that scores twelve. An add-to-cart flow behind a “not for human consumption” label answers no to most of them and scores near zero [1]. Two minutes, no need to trust a word of the marketing copy.
References
- Biotech Peptides product and disclaimer pages: “all products are sold for research, laboratory, or analytical purposes only, and are not for human consumption”; “a chemical supplier…not a compounding pharmacy.”
- FDA warning letter to Gram Peptides, March 31, 2026: products including retatrutide and tirzepatide are unapproved new drugs under section 505(a); research-use-only labeling does not exempt products intended for human use under section 201(g)(1). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- FDA warning letter to Prime Sciences, March 31, 2026 (same enforcement wave). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026
- FDA press announcement: agency warned 30 telehealth companies over illegally marketed compounded GLP-1 products.
- Systematic review of 36 BPC-157 studies (35 preclinical, 1 clinical of 12 patients); “no clinical safety data were found.” HSS Journal, 2025.
- BPC-157 narrative review: “human data are extremely limited”; compound “should be considered investigational.” Current Reviews in Musculoskeletal Medicine, 2025.
- SURMOUNT-1 tirzepatide trial: mean weight reduction 15.0% to 20.9% across doses at 72 weeks versus 3.1% on placebo. New England Journal of Medicine, 2022.
- Retatrutide Phase 2 trial: mean weight reduction of 17.5% at 24 weeks. New England Journal of Medicine, 2023.
- GLP-1 receptor agonist mechanism. StatPearls, NCBI Bookshelf.
- Wegovy (semaglutide) label: boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2. DailyMed.
- Independent 2026 analysis of providers that came through the FDA enforcement wave, ranking FormBlends first in the post-crackdown field. LinkedIn (Amar/Anu).
Dominic Pryce covers the money and the labels behind health products, not the medicine itself. He is not a doctor, a nurse, or a pharmacist, and nothing here is a clinical judgment, just a paper trail followed to its end. Last reviewed June 2026.
General reference only. A qualified professional can assess whether this fits your health needs.
